Diabetes-altered gene expression in rat skeletal muscle corrected by oral administration of vanadyl sulfate

Physiological Genomics

Volumn 26, Issue 3, 2006, Pages 192-201

  Willsky, Gail R ^a   Chi, Lai Har ^a   Liang, Yulan ^b   Gaile, Daniel P ^b   Hu, Zihua ^b   Crans, Debbie C ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Microarray; Streptozotocin; Vanadium

Indexed keywords

CHOLESTEROL; FATTY ACID; REACTIVE OXYGEN METABOLITE; STREPTOZOCIN; TRIACYLGLYCEROL; VANADYL SULFATE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; GENE EXPRESSION; GENE IDENTIFICATION; HYPERGLYCEMIA; HYPERLIPIDEMIA; LIPID METABOLISM; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; RAT; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS, EXPERIMENTAL; FATTY ACIDS, NONESTERIFIED; GENE EXPRESSION; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; MALE; MUSCLE, SKELETAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXIDATIVE STRESS; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRIGLYCERIDES; VANADIUM COMPOUNDS;

ANIMALIA;

EID: 33747373821     PISSN: 10948341     EISSN: 15312267     Source Type: Journal    
DOI: 10.1152/physiolgenomics.00196.2005     Document Type: Article

References (56)

1. Anderson RA. Chromium in the prevention and control of diabetes. Diabetes Metab 26: 22-27, 2000.
2. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, and Sherlock G. Gene Ontology: tool for the unification of biology. Nat Genet 25: 25-29, 2000.
3. Baranano DE, Rao M, Ferris CD, and Snyder SH. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci USA 99: 16093-16098, 2002.
4. Battell ML, Yuen VG, and McNeill JH. Treatment of the BB rats with vanadyl sulfate. Pharmacol Commun 1: 291-301, 1992.
5. Benjamini Y and Hockberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc 57: 289-300, 1995.
6. Benson DA, Karsch-Mizrachi I, Lipman DJ, Ostell J, and Wheeler DL. GenBank: update. Nucleic Acids Res 32: D23-D26, 2004.
7. Bilan PJ, Moyers JS, and Kahn CR. The ras-related protein Rad associates with the cytoskeleton in a non-lipid-dependent manner. Exp Cell Res 242: 391-400, 1998.
8. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM [erratum appears in Diabetes 1997 Mar; 46(3): 536]. Diabetes 46: 3-10, 1997.
9. Boden G, Chen X, Ruiz J, van Rossum GD, and Turco S. Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Metabolism 45: 1130-1135, 1996.
10. Brownlee M. Banting Lecture 2004: The pathophysiology of diabetic complications, a unifying mechanism. Diabetes 54: 1615-1625, 2005.
11. Buglyó P, Crans DC, Nagy EM, Lindo RL, Yang L, Smee JJ, Jin W, Chi LH, Godzala Iii ME, and Willsky GR. Aqueous chemistry of the vanadium(III) (V(III)) and the V(III)-dipicolinate systems and a comparison of the effect of three oxidation states of vanadium compounds on diabetic hyperglycemia in rats. Inorg Chem 44: 5416-5427, 2005.
12. Cam MC, Brownsey RW, and McNeill JH. Mechanisms of vanadium action: insulin-mimetic or insulin-enhancing agent? Can J Physiol Pharmacol 78: 829-847, 2000.
13. Clodfelder BJ, Upchurch RG, and Vincent JB. A comparison of the insulin-sensitive transport of chromium in healthy and model diabetic rats. J Inorg Biochem 98: 522-533, 2004.
14. Cohen N, Halberstam M, Shlimovich P, Chang CJ, Shamoon H, and Rossetti L. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 95: 2501-2509, 1995.
15. Cusi K, Cukier S, DeFronzo RA, Torres M, Puchulu FM, and Redondo JC. Vanadyl sulfate improves hepatic and muscle insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab 86: 1410-1417, 2001.
16. Drake PG and Posner BI. Insulin receptor-associated protein tyrosine phosphatase(s): role in insulin action. Mol Cell Biochem 182: 79-89, 1998.
17. Fernandez-Alvarez J, Barbera A, Nadal B, Barcelo-Batllori S, Piquer S, Claret M, Guinovart JJ, and Gomis R. Stable and functional regeneration of pancreatic beta-cell population in nSTZ-rats treated with tungstate. Diabetologia 47: 470-477, 2004.
18. Fernandez-Real JM, Lopez-Bermejo A, and Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes 51: 2348-2354, 2002.
19. Field CJ and Butler SC. The BB rat: a unique model of human type I diabetes. In: Experimental Models of Diabetes, edited by McNeill JH. Boca Raton, FL: CRC, 1999, p. 295-336.
20. Fugono J, Yasui H, and Sakurai H. Improvement of diabetic states in streptozotocin-induced type 1 diabetic rats by vanadyl sulfate in enteric-coated capsules. J Pharm Pharmacol 57: 665-669, 2005.
21. Gatjens J, Meier B, Kiss T, Nagy EM, Buglyo P, Sakurai H, Kawabe K, and Rehder D. A new family of insulin-mimetic vanadium complexes derived from 5-carboalkoxypicolinates. Chem A Euro J 9: 4924-4935, 2003.
22. Genet S, Kale RK, and Baquer NZ. Alterations in antioxidant enzymes and oxidative damage in experimental diabetic rat tissues: effect of vanadate and fenugreek (Trigonellafoenum graecum). Mol Cell Biochem 236: 7-12, 2002.
23. Goldfine AB, Patti ME, Zuberi L, Goldstein BJ, LeBlanc R, Landaker EJ, Jiang ZY, Willsky GR, and Kahn CR. Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies. Metab Clin Exp 49: 400-410, 2000.
24. Goldstein BJ, Kalyankar M, and Wu X. Redox Paradox: insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targets. Diabetes 54: 311-321, 2005.
25. Goldwaser I, Gefel D, Gershonov E, Fridkin M, and Shechter Y. Insulin-like effects of vanadium: basic and clinical implications. J Inorg Biochem 80: 21-25, 2000.
26. Heyliger CE, Tahiliani AG, and McNeill JH. Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. Science 227: 1474-1477, 1985.
27. Hu PC, Kong X, Velleca M, and Lawrence JC Jr. Molecular cloning and tissue distribution of PHAS-I, an intracellular target for insulin and growth factors. Proc Natl Acad Sci USA 91: 3730-3734, 1994.
28. Kanz C, Aldebert P, Althorpe N, Baker W, Baldwin A, Bates K, Browne P, van den Broek A, Castro M, Cochrane G, Duggan K, Eberhardt R, Faruque N, Gamble J, Diez FG, Harte N, Kulikova T, Lin Q, Lombard V, Lopez R, Mancuso R, McHale M, Nardone F, Silventoinen V, Sobhany S, Stoehr P, Tuli MA, Tzouvara K, Vaughan R, Wu D, Zhu W, and Apweiler R. The EMBL nucleotide sequence database. Nucleic Acids Res 33: D207-D302, 2005.
29. Knoll KE, Pietruscz JL, and Liang M. Tissue-specific transcriptome responses in rats with early streptozotocin-induced diabetes. Physiol Gemonics 21: 222-229, 2005.
30. Li N and Karin M. Is NF-kappaB the sensor of oxidative stress? FASEB J 13: 1137-1143, 1999.
31. -. Arch Biochem Biophys 279: 1-7, 1990.
32. Lohr JW, Bennett MI, Pochal MA, McReynolds J, Acara M, and Willsky GR. Effect of vanadate on renal hypertrophy and sorbitol accumulation in streptozotocin induced diabetes in rats. Res Commun Chem Pathol Pharmacol 72: 191-202, 1991.
33. Lyonnet M and Martin E. L'emploi therapeutique des derives du vanadium. La Presse Medicale 32: 191-192, 1899.
34. 2 and plays an integral role in insulin signal transduction. Mol Cell Biol 24: 1844-1854, 2004.
35. Marzban L and McNeill JH. Insulin-like actions of vanadium: potential as a therapeutic agent. J Trace Elements Exp Med 16: 253-267, 2003.
36. Ozcelikay AT, Becker DJ, Ongemba LN, Pottier AM, Henquin JC, and Brichard SM. Improvement of glucose and lipid metabolism in diabetic rats treated with molybdate. Am J Physiol Endocrinol Metab 270: E344-E352, 1996.
37. Patel MS and Korotchkina LG. Mini Series: modern metabolic concepts. The biochemistry of the pyruvate dehydrogenase complex. Biochem Mol Biol Ed 31: 5-15, 2003.
38. Portik-Dobos V, Anstadt MP, Hutchinson J, Bannan M, and Ergul A. Evidence for a matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes. Diabetes 51: 3063-3068, 2002.
39. Qiu W, Avramoglu RK, Dube N, Chong TM, Naples M, CA, Sidiropoulos KG, Lewis GF, Cohn JS, Trmblay ML, and Adeli K. Hepatic TRP-1B Expression regulates the assembly and secretion of apolipoprotein B-containing lipoproteins. Evidence from protein tyrosine phosphatase-1B overexpression knockout and RNAi studies. Diabetes 53: 3057-3066, 2005.
40. Raza H, Prabu SK, Robin MA, and Avadhani NG. Elevated mitochondrial cytochrome P450 2E1 and glutathione S-transferase A4-4 in streptozotocin-induced diabetic rats: tissue-specific variations and roles in oxidative stress. Diabetes 53: 185-194, 2004.
41. Robertson RP, Harmon J, Tran PO, Tanaka Y, and Takahashi H. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 52: 581-587, 2003.
42. Rodrigues B, Poucheret P, Battell ML, and McNeill JH. Streptozotocin-induced diabetes: induction, mechanism(s) and dose dependency. In: Experimental Models of Diabetes, edited by McNeill JH. Boca Raton, FL: CRC Press LLC, 1999, p. 3-17.
43. Ross I and Gentleman RR. A language for data analysis and graphics. J Comput Graph Stat 5: 229-314, 1996.
44. Rousset S, Alves-Guerra MC, Mozo J, Miroux B, Cassard-Doulcier AM, Bouillaud F, and Ricquier D. The biology of mitochondrial uncoupling proteins. Diabetes 53: S130-S135, 2004.
45. Rusnak F and Reiter T. Sensing electrons: protein phosphatase redox regulation. Trends Biochem Sci 25: 527-529, 2000.
46. Salmeen A, Andersen JN, Myers MP, Meng TC, Hinks JA, Tonks NK, and Barford D. Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate. Nature 423: 769-773, 2003.
47. Saltiel AR and Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414: 799-806, 2001.
48. Tabatabaie T, Vasquez-Weldon A, Moore DR, and Kotake Y. Free radicals and the pathogenesis of type 1 diabetes: beta-cell cytokine-mediated free radical generation via cyclooxygenase-2. Diabetes 52: 1994-1999, 2003.
49. Tewari M, Dobrzanski P, Mohn KL, Cressman DE, Hsu JC, Bravo R, and Taub R. Rapid induction in regenerating liver of RL/IF-1 (an I kappa B that inhibits NF-kappa B, RelB-p50, and c-Rel-p50) and PHF, a novel kappa B site-binding complex. Mol Cell Biol 12: 2898-2908, 1992.
50. Thompson KH, Chiles J, Yuen VG, Tse J, McNeill JH, and Orvig C. Comparison of anti-hyperglycemic effect amongst vanadium, molybdenum and other metal maltol complexes. J Inorg Biochem 98: 683-690, 2004.
51. Thornalley PJ, McLellan AC, Lo TW, Benn J, and Sonksen PH. Negative association between erythrocyte reduced glutathione concentration and diabetic complications. Clin Sci (Lond) 91: 575-582, 1996.
52. Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H, Aljada A, and Dandona P. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 52: 2882-2887, 2003.
53. Willsky GR, White DA, and McCabe BC. Metabolism of added orthovanadate to vanadyl and high-molecular-weight vanadates by Saccharomyces cerevisiae. J Biol Chem 259: 13273-13281, 1984.
54. Yang L, Crans DC, Miller SM, La Cour A, Anderson OP, Kaszynski PM, Godzala ME III, Austin LD, and Willsky GR. Cobalt(II) and Cobalt(III) dipicolinate complexes: solid state, solution, and in vivo insulin-like properties. Inorg Chem 41: 4859-4871, 2002.
55. Yechoor VK, Patti ME, Saccone R, and Kahn CR. Coordinated patterns of gene expression for substrate and energy metabolism in skeletal muscle of diabetic mice. Proc Natl Acad Sci USA 99: 10587-10592, 2002.
56. Yoshida K, Hirokawa J, Tagami S, Kawakami Y, Urata Y, and Kondo T. Weakened cellular scavenging activity against oxidative stress in diabetes mellitus: regulation of glutathione synthesis and efflux. Diabetologia 38: 201-210, 1995.